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ABSTRACT 
Medicinal plants have been suggested since ancient times to be a good source of drugs 
for treating diabetes. The aims of this thesis were to identify the anti-diabetic effects 
and to understand further the mechanisms involved for two traditional plants, borapetol 
B (C1) isolated from Tinospora crispa, and Gynostemma pentaphyllum (GP), in 
diabetic rats. The effects of GP extract on innate immune mechanisms in the urinary 
tract were also investigated.  
 
In Paper I, an oral administration of C1 significantly decreased blood glucose levels 
and increased plasma insulin levels in treated rats, compared to placebo groups, in both 
Wistar (W) and diabetic Goto Kakizaki (GK) rats. C1 dose-dependently increased 
insulin secretion from W and GK rat islets. In perifusions of W and GK rat islets, 
insulin secretion was increased by C1 in low and high glucose, and returned to basal 
levels when C1 was omitted, indicating that the compound did not cause leakage of 
insulin by damaging islet beta cells. This study provides evidence that C1 possesses 
anti-diabetic properties mainly due to its stimulation of insulin release. 
 
In Paper II, when exploring the mechanisms of insulin release in W and GK pancreatic 
islets, we showed that the C1 effect was partly via K-ATP channels, since the 
potassium channel blocker diazoxide partly but not totally suppressed C1 stimulation at 
16.7 mM glucose. The C1 effect was also dependent on L-type Ca2+ channels, since the 
calcium blocker nifedipine suppressed the insulin response to C1 at 16.7 mM glucose. 
There was no modulation by PKA and PKC inhibitors. Furthermore, the C1 effect was 
partly dependent on pertussis toxin sensitive Ge-protein. Therefore, the major 
stimulatory effect of C1 might be on the process of exocytosis. 
 
In Paper III, two weeks’ treatment with GP extract in GK rats significantly improved 
blood glucose, plasma insulin levels and insulin secretion from islets isolated from the 
treated rats. Futhermore, when tested in vitro, GP extract dose-dependently stimulated 
insulin release from the isolated rat islets at high glucose concentrations. GP-induced 
insulin release is partly mediated via K-ATP and L-type Ca2+ channels. The effects of 
GP were also mediated via the PKA system, and partly dependent on pertussis toxin 
sensitive Ge-protein at high glucose concentrations. 
 
In Paper IV, ex vivo infection experiments demonstrated that the pro-inflammatory 
response to E. coli was attenuated in bladder tissue from diabetic GK rats receiving GP 
extract, compared to untreated rats. In vitro assays using uroepithelial cells challenged 
with E. coli corroborated these results. Moreover, GP treatment modulated the 
expression of antimicrobial peptides. With these properties, GP might be a beneficial 
supplement for diabetic patients with a history of urinary tract infection. 
 
Keywords: Type 2 diabetes, Goto Kakizaki rat, insulin secretion, anti-inflammatory, 
antimicrobial peptides 
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1 INTRODUCTION 
 
1.1 TYPE 2 DIABETES 
Type 2 diabetes (T2D) is an endocrine metabolic disorder characterized by 
hyperglycaemia due to impaired insulin secretion and insulin resistance [1-3] (Figure 
1). Impaired insulin secretion is associated with beta-cell secretory dysfunction and/or 
diminished beta-cell mass, which results in the failure of islets to secrete adequate 
amounts of insulin in order to achieve normoglycaemia [4]. The failure of pancreatic 
islets to secrete sufficient levels of insulin in response to elevated blood glucose 
concentrations reduces insulin signaling in its target tissues, which include the liver, 
muscle and adipocytes. This leads to decreased glucose uptake by the muscles, 
increased glucose output by the liver and increased lipolysis in the fat tissues. The 
increased levels of glucose and fatty acids in the bloodstream lead to both reduced 
insulin secretion and insulin resistance [5,6].  
 
 
 
Figure 1: The schematic model of T2D development. 
 
The number of people with diabetes is increasing worldwide and is expected to rise 
from 366 million in 2011 to 552 million in 2030 [7]. Several factors lead to the 
development of diabetes, including an aging population, genetic factors, sedentary life 
style, obesity and an unhealthy diet [8,9]. Complications in diabetes are both 
macrovascular (heart attack, stroke and peripheral vascular disease) and microvascular 
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(neuropathy, retinopathy and nephropathy), which lead to increased morbidity and 
mortality [10].  
1.1.1 Insulin secretion pathway in pancreatic beta islets 
 
The K-ATP channel -dependent and -independent pathways are two major signaling 
processes involved in controlling insulin secretion and maintaining the regulation of 
glucose homeostasis in pancreatic islets [4,11]. In the K-ATP channel-dependent 
pathway, glucose enters the beta cells via glucose transporter 2 (GLUT-2). Glucose is 
phosphorylated to glucose-6-phosphate (G6P) by glucokinase; subsequent glycolysis 
and glucose oxidation steps generate ATP, which leads to an increase in the cellular 
adenosine triphosphate/adenosine diphosphate (ATP/ADP) ratio (Figure 2). This results 
in the closure of K-ATP channel-dependent channels, causing membrane depolarization 
and the opening of voltage-dependent Ca2+ channels, which facilitates the entry of free 
extracellular Ca2+ into the beta cells, causing increased cytosolic Ca2+ levels and 
stimulated insulin release by exocytosis [12-14]. The K-ATP channel-independent 
pathway, in which glucose exerts direct stimulatory effects on the exocytosis of insulin, 
works in synergy with the K-ATP channel-dependent pathway [11,15]. 
 
 
 
Figure 2: Schematic  model  of  glucose  induced  insulin  secretion  in  pancreatic  β-cells 
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Second messengers such as cyclic adenosine monophosphate (cAMP) and 
diacylglycerol (DAG) increase insulin release via protein kinase A (PKA) and protein 
kinase C (PKC) pathways [16]. Guanyl nucleotide-binding (GTP-coupled) proteins, 
also known as G proteins, are involved in the process of exocytosis [17,18]. Several 
inhibitors were used to block insulin release in order to understand the mechanism by 
which herbal plant extracts regulate insulin secretion (Figure 3). Diazoxide acts on the 
K-ATP site by opening K-ATP channels, which results in an increase of intracellular 
K+ and thus inhibits insulin release [12]. Nifedipine plays an important role in the Ca2+ 
channel closure by blocking Ca2+ influx, thereby inhibiting insulin release [19]. While 
an increase in the intracellular Ca2+ concentration is the principal signal in insulin 
secretion, other intracellular signals such as cAMP and DAG also are important in the 
regulation of exocytosis through protein phosphorylation mediated by PKA and PKC, 
respectively [11,15]. H89 and calphostin C are used to block the PKA and PKC 
systems, respectively. G-proteins are involved in signal transduction in many tissues, 
and act as mediators of hormonal inhibition of insulin release [20]. Gi protein is known 
to be involved in the inhibition of adenylyl cyclase, whereas Ge protein acts during 
insulin exocytosis [17]. Both Ge and Gi proteins are inhibited by pertussis toxin 
(expressed by Bordetella pertussis) via ADP-ribosylation [20,21]. 
 
 
Figure 3: Schematic model of the inhibitors used to understand the effects of Tinospora crispa and 
Gynostemma pentaphyllum on the  insulin  secretion  in  pancreatic  β-cells 
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1.1.2 Urinary tract infection (UTI) in type 2 diabetes mellitus 
 
Urinary tract infection (UTI) is a common infection detected in type 2 diabetes patients 
[22-24]. UTIs can be divided into cystitis, pyelonephritis and urosepsis, depending on 
which part of the urinary tract is involved. In addition, catheter-related bacteriuria and 
infections frequently occur in association to urinary catheters [25]. The clinical 
symptoms of UTI include dysuria, frequent micturations, abdominal distention and 
fever [26]. Women are more often affected by UTI than men, and diabetes is an 
additional risk factor [26,27]. Due to increasing antibiotic resistance among bacteria, 
there is a search for more effective drugs to replace currently available conventional 
antibiotics, which have become less effective over time.  
 
Susceptibility to bacterial infection increases in parallel with the duration and severity 
of diabetes. It has previously been shown that the presence of E. coli in urine was 
significantly higher in diabetic patients, and that an increased level of glycosylated 
hemoglobin (HbA1c) predisposes diabetic patients to UTI [24,28]. Increased adherence 
of bacteria to uroepithelial cells, the presence of glycosuria, and neutrophil dysfunction 
predispose diabetic individuals to genital infections and UTI [22,23,29]. The overall 
elevated levels of pro-inflammatory cytokines found in diabetic patients have also been 
suggested to contribute to the development of UTI [30]. Interleukin (IL)-6 and IL-8 are 
important inflammatory cytokines in bacterial infections which are produced in 
response to bacterial pathogens [31]. 
 
Apparently, a high glucose content in the urine, which facilitates bacterial growth and a 
defective host immune response, predisposes diabetes patients to infection due to 
impaired phagocytic functions such as chemotaxis and phagocytosis. Hyperglycaemia 
leads to neutrophil dysfunction by increasing intracellular calcium levels and 
interfering with actin, diapedesis and phagocytosis [32]. Other factors, including age, 
diabetic nephropathy and vascular complications, all increase the risk of UTIs in 
diabetic patients [23]. 
 
1.2 TREATMENT OF TYPE 2 DIABETES WITH TRADITIONAL PLANTS 
 
The current treatment of T2D includes anti-diabetic agents such as sulphonylureas, 
biguanides and incretins. When these drugs fail to correct hyperglycaemia, insulin 
theraphy is initiated. However, the presence of a number of adverse effects with 
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conventional drugs has stimulated the search for more effective anti-diabetic drugs 
from medicinal plant sources which exhibit comparatively less side effects [33-36]. 
 
Medicinal plants have been suggested since ancient times to be a good source of 
medicine for the treatment of diabetes.  The anti-diabetic properties of medicinal plants 
are attributed to the presence of several substances such as glycosides, alkaloids, 
terpenoids, flavonoids and others. Currently, there are about 800 plants which are 
reported to possess anti-diabetic properties both in in vivo and in in vitro studies. Several 
medicinal plant parts have demonstrated promising results in terms of achieving 
normoglycemia by improving insulin secretion from pancreatic beta cells, while others 
have been shown to increase glucose uptake in adipose and skeletal muscle, to improve 
hepatic insulin sensitivity and to suppress glucose absorption in the intestinal tract. 
However, further investigations are needed, since not all medicinal plants have been 
properly evaluated and characterized in terms of the mechanism of action, long term 
side effects and toxicity [1,9].  
 
1.2.1 Tinospora crispa 
Tinospora crispa (T. crispa) belongs to the family of Menispermaceae, and is known to 
the Malays by various vernacular names  such  as  ‘akar  patawali’  or  ‘akar  seruntum’.  It  is  
an indigenous climber plant that commonly grows wild in Asian countries from the 
southwestern part of China to Southeast Asia, including Malaysia [37,38]. It has been 
used in traditional medicine for various healing puposes including septicaemia, fever, 
malaria and others [37,39]. Several studies have confirmed that T. crispa possesses 
antioxidant properties and also anti-proliferative effects on selected human cancer cell 
lines [40-42]. Other studies have shown that T. crispa exhibits anti-inflammatory [43], 
immunomodulatory [44] and anti-malarial properties [45]. It has been shown as well that 
T. crispa helps to maintain blood pressure and heart rate in anesthetized rats [46]. The 
anti-diabetic effects of T. crispa extract have been clearly demonstrated both in vivo and 
in vitro, and include improving insulin secretion and insulin sensitivity [38,47-50]. 
 
1.2.2 Gynostemma pentaphyllum 
 
Gynostemma Pentaphyllum (GP) Makino, also known as Jiao Gu Lan, is a climbing 
perennial vine plant which grows in several parts of Asian countries including China, 
Vietnam, Japan and Malaysia [51,52]. 
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of GP as claimed by practitioners have been pharmacologically and clinically proven in 
several studies. GP has been reported previously to have a high radical scavenging 
capacity, as well as anti-proliferative, anti-inflammatory [51,53,54], hypoglycemic 
[55,56], anti-cancer [57,58] and anti-microbial effects [59]. 
 
Gypenosides are saponins isolated from GP, and currently there are about 90 different 
gypenosides that have been isolated and characterized. Randomized clinical trials and 
experiments in an animal model of T2D have demonstrated that GP exerts a 
significant anti-diabetic effect by enhancing insulin sensitivity [60-62] and insulin 
secretion [63-65]. The anti-diabetic effects and the insulin release mechanisms of a 
gypenoside (phanoside) compound isolated from GP have also been identified [63]. 
Furthermore, using diabetic rat models, GP saponins were found to be associated 
with the regulation of glycemia, dyslipidemia and immunocompetence with 
antioxidant activities [66,67]. 
 
Previous studies have also shown the anti-inflammatory effects of extracts using 
different types of cell cultures. Components of GP have previously been observed to 
exhibit anti-inflammatory properties in cell lines by inhibiting the nuclear factor (NF) 
κB   [68] and the inflammatory mediators IL-1β,   IL-6, TNF-α   and   COX-2 mRNA 
[51,53,69]. 
 
1.3 GOTO-KAKIZAKI (GK) RAT 
 
The GK rat strain is an inbred non-obese model of T2D that displays mild fasting 
hyperglycemia mainly due to impaired insulin secretion and a degree of insulin 
resistance. In the GK rat, glucose intolerance is most likely primarily due to reduced 
beta cell mass and impaired beta cell function. The morphological feature of GK rat 
pancreatic islets is starfish-shaped islets due to fibrosis [70-72]. 
 
Established by Goto and collaborators in Sendai, Japan in 1970s, this rat substrain was 
derived from normoglycemic Wistar (W) rats by selective repeated inbreeding in each 
successive generation of the siblings with the highest blood glucose levels, as identified 
by an oral glucose tolerance test. The glucose intolerance and impairment of glucose-
induced insulin release have been constant features of the GK rat [70,72]. Impaired 
glucose-stimulated insulin secretion has been shown in vivo [73], in perifused isolated 
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pancreatic islets [72,73] and in isolated pancreatic islets [72,74]. GK rats also exhibit 
impaired insulin sensitivity in the liver, skeletal muscle and adipose tissues [75,76]. 
 
Although there are differences in islet cell morphology and islet metabolism in some 
GK rat colonies, common features between the colonies include reduced beta cell mass, 
mild hyperglycemia, insulin resistance and a lean phenotype [77]. At the embryonic 
stage of 16 weeks, the beta cell mass is only half of that of normal W rats, and the 
fetuses show both decreased insulin levels [78]. Basal hyperglycemia and decreased 
insulin levels are detectable at 3 weeks after birth due to defects in the neonatal beta 
cell mass [79].  
 
The GK rat model has been used not only for studies of complications in diabetes 
(retinopathy, neuropathy and nephropathy) [80-82], but also in investigations of 
defective of insulin release [72] and hypertension. These reports have shown that both 
acute and chronic hyperglycemia increase islet capillary pressure [83]. In conclusion, 
the GK rat has been widely used in experimental diabetes research, and can be regarded 
as one of the best available rodent strains for the study of inherited T2D. 
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2 AIMS 
 
The aim of this thesis was to investigate the anti-diabetic effects of two plants used in 
traditional medicine, Tinospora crispa and Gynostemma pentaphyllum (GP) in an 
animal of type 2 diabetes, the Goto Kakizaki rat. The effects of GP extract on innate 
immune mechanisms in the urinary tract were also identified.  
The specific aims of the individual papers were: 
 
I. To evaluate the anti-diabetic effects of borapetol B (C1) isolated from 
Tinospora crispa in vivo and in isolated rat pancreatic islets. 
 
II. To identify the mechanisms by which borapetol B (C1) isolated from Tinospora 
crispa stimulates insulin secretion in rat pancreatic islets. 
 
III. To elucidate the anti-diabetic effects of GP extract, and to understand the 
mechanisms behind its stimulation of insulin release. 
 
IV. To investigate if oral administration of GP extract exhibits immune-modulatory 
properties in the urinary bladder of rats, and to identify the resulting changes in 
the expression of pro-inflammatory cytokines and antimicrobial peptides.  
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3 MATERIALS AND METHODS 
 
3.1 RAT MODELS 
 
Male normoglycemic control Wistar (W) and spontaneously type 2 diabetic Goto-
Kakizaki (GK) rats (200-350 g) were used in this study. GK rats, originating from W 
rats, were bred in our department [72]. W rats were purchased from a commercial 
breeder (Charles River). The animals were kept at 22°C with an alternating 12-hour 
light-dark cycle (6 am to 6 pm) and were allowed access to food and water before 
being anesthetized for isolation of pancreatic islets. The study was approved by the 
Laboratory Animal Ethics Committee of the Karolinska Institutet. 
 
3.2 PLANT MATERIALS 
 
3.2.1 Tinospora crispa  
 
Tinospora crispa stems were collected in Kota Belud (Sabah, Malaysia) in May 2005, 
identified by Berhaman Ahmad (Universiti Malaysia Sabah) and voucher specimen 
(FRI54832) deposited at the Forest Research Institute Malaysia. Isolation and 
purification of borapetol B (C1) from T. crispa were modified from a previous study 
[44,84,85].  
 
During the isolation procedure, fractions stimulating insulin secretion in a bioassay 
with isolated pancreatic islets from W rats were selected for subsequent purification. 
The stem powder (5 kg) was extracted by sonicating with solvents at room temperature 
(25∘C) for 15 minutes. It was first defatted with hexane followed by methanol-water 
(4:1) solvent extraction. Extracts were consolidated and reduced to one-third volume by 
vacuum evaporation yielding a brown syrup. The syrup was acidified to pH 2 with 
sulphuric acid (50% v/v) and partitioned four times with chloroform. The chloroform 
layer was evaporated to dryness to obtain brownish mass which showed prominent 
insulin stimulatory effect. The brown mass was chromatographed over normal phase 
silica gel eluted with 100% chloroform followed by chloroform methanol (9.5: 0.5) and 
subsequently increasing eluent polarity with methanol.  
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Chromatographic fractions were monitored by thin layer chromatography (TLC) 
visualized at 365 nm. Fractions containing spots possessing Rf value within the range 
of 0.20 to 0.75 (chloroform methanol 9.5:0.5) were examined further as these fractions 
were also inducing insulin secretion. These fractions were consolidated and re-
chromatographed to yield 10 subfractions. When cooled (4∘C), subfractions seven and 
eight yielded colourless crystals. Upon recrystallization with chloroform-methanol, 
crystals (450 mg) were recovered by vacuum filtration and washed with cold 
chloroform. TLC revealed a single compound known as C1 which stimulated insulin 
secretion. The identity of C1 as borapetol B was further confirmed using 1H-NMR 
[86]. The compound was suspended to a stock solution of 320 µg of C1 diluted in 640 
µl of 3.3 mM KRB buffer with 5% of DMSO for in vitro experiments (Paper I); and to 
240 µg of C1 diluted in 21 ml of water with 5% of DMSO (Paper II) for the treatment 
of animals.  
 
3.2.2 Extraction procedure of Gynostemma pentaphyllum  
 
GP water extracts were prepared according to standardized procedures from the whole 
herb (Legosan Co., Kumla, Sweden) and consists of 98% gypenosides (German LEFO-
Institut für Lebensmittel und Umwelt GmbH, Ahrensburg, Germany). The dried extract 
was suspended to a stock solution of 10 mg/ml PBS for in vitro experiments (Paper 
IV); and to 0.85 mg/20 ml (Paper III) water for the treatment of animals. 
 
3.3 ORAL GLUCOSE TOLERANCE TEST 
 
An oral glucose tolerance test was performed to identify the effect of C1 (Paper I) and 
GP (Paper III) on the blood glucose levels. C1 (10 µg/100 g of body weight) was 
given orally 30 min prior to the OGTT (Paper I) to W and GK rats whereas GP (0.03 
g/100 g of body weight) was administrated orally to GK for 2 weeks (Paper III). The 
rats were fasted overnight (14 to 15 hours), allowing access only to plain drinking 
water. Blood for glucose determination was obtained by tail-prick method at different 
time points: 0 minute (before glucose load at 2 mg/g body weight), then at 30, 60, and 
120 minutes (Paper I) post glucose administration or at 30, 60, 90, 120 and 150 
minutes (Paper III). Blood glucose level was measured using a glucometer, Accu-
check Aviva (Roche Diagnostic GmbH, USA). Blood samples were collected for the 
measurement of plasma insulin level (about 20 µl/blood sample) at 0 and 30 min 
(Paper I) and 0, 30 and 120 minutes (Paper III). 
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3.4 TISSUE COLLECTION 
 
After two weeks’ treatment with GP, the animals were euthanized using CO2. Islets 
(Paper III) and bladder tissues (Paper IV) were collected immediately for further 
analysis and kept in -80ºC. 
 
3.5 ISOLATION OF PANCREATIC ISLETS 
 
The isolation of islets was performed using collagenase digestion method (Paper I, II, 
III) [63].   The   islets  were  washed   several   times  with  Hank’s   Balanced   Salt   Solution 
(HBBS), and then hand-picked under a stereomicroscope and cultured for 24 hours at 
37°C, with an atmosphere of 5% CO2-95% air in RPMI 1640 culture medium (SVA, 
Sweden) supplemented with 30 mg L-glutamine (Sigma-Aldrich, USA), 11 mM 
glucose (Sigma-Aldrich, USA), antibiotics (100 IU/ml penicillin and 0.1 mg/ml 
streptomycin) (Invitrogen, USA). Inactivated fetal calf serum (10 %) was added to the 
culture medium. 
 
3.6 BATCH INCUBATIONS FOR INSULIN SECRETION 
 
Following overnight culture, islets were pre-incubated at 3.3 mM glucose at 37°C with 
an atmosphere of 5% CO2 – 95% air for 30 to 45 min. The islets were further incubated 
with different concentrations of compound in a slowly shaking 37°C waterbath for 60 
min. C1 was tested at 10, 1, 0.1 µg/ml (Paper I). GP was tested at 15, 10, 5, 1 mg/ml 
(Paper III). The medium used was Krebs-Ringer bicarbonate (KRB) buffer solution 
containing 10 mmol/l HEPES (Sigma-Aldrich, USA) and 0.2% bovine serum albumin. 
After incubation, 200 µl of the medium were transferred to new tubes for RIA and kept 
in freezer -20°C until assayed for insulin secretion. 
 
3.7 PERIFUSIONS OF ISLETS 
 
Perifusions of islets were done to investigate how the C1 substance affects the kinetics 
of insulin release [63] (Paper I). Islets were perifused with medium containing 10 
µg/ml of C1 at 3.3 mM  and 16.7 mM glucose using a peristaltic pump (Ismatec SA, 
Zurich, Switzerland) [87]. Fractions (200 µl) of the perifusion medium were collected 
for radioimmunoassay of insulin [88]. 
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3.8 EFFECTS OF TRADITIONAL PLANTS ON THE INSULIN SECRETION 
FROM ISLETS 
 
To investigate mechanisms behind effects of C1 and GP extract on insulin secretion, rat 
islets were incubated in both KRB containing 3.3 mM and 16.7 mM glucose (Paper II, 
III). The medium was added with different incubation mixtures and inhibitors; 0.25 
mM diazoxide (Sigma-Aldrich, USA) only (to open the K-ATP channels); 50 mM of 
KCl (for depolarization of beta cells). To investigate the effects of compounds on L-
type Ca2+ channels on insulin secretion, rat islets were incubated in both KRB 
containing 3.3 mM and 16.7 mM glucose with addition of L-type Ca2+ channel 
inhibitor, nifedipine (Sigma-Aldrich, USA). To investigate the effect of C1 and GP in 
the presence of protein PKC and PKA on insulin release, rat islets were incubated with 
or without compounds and the PKA-inhibitor, H89 (10 uM) (Sigma-Aldrich, USA) or 
the PKC inhibitor, calphostin-C (1.5 uM) (Sigma-Aldrich, USA) for 60 min in KRB 
containing 3.3 mM and 16.7 mM glucose. 
 
To assess the possible involvement of exocytotic G-protein induced by C1 and GP 
extract in insulin release, rat islets were pretreated at 37°C overnight with 100 ng/ml 
pertussis toxin, RPMI 1640 culture medium containing 11 mM glucose. The islets 
exposed overnight with or without pertussis toxin were incubated with C1 and GP 
extract at 3.3 mM and 16.7 mM glucose to study insulin secretion. 
 
3.9 MEASUREMENT OF INSULIN SECRETION FROM ISLETS 
 
Aliquots obtained from batch incubations (Paper I, III), perifusions (Paper I) and the 
insulin release experiments (Paper II, III) were analyzed for insulin content using RIA 
[88]. 
 
3.10 BACTERIA 
 
The uropathogenic E. coli strain CFT073 was used for all infection experiments. 
Bacteria from frozen stock were cultured on blood agar plates overnight at 37ºC and 
then inoculated into 3 ml of LB broth for another overnight culture. This overnight 
culture was diluted 1:100 into fresh LB broth and grown until bacteria reached the 
logarithmic growth phase. Bacteria were collected by centrifugation and washed once 
with PBS. Then, the bacterial density was adjusted to an OD=0.125 at 600 nm, 
corresponding to approximately 108 CFU/ml. 
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3.11 AGAR DIFFUSSION ASSAY  
 
The sensitivity assay was carried out to test the antimicrobial activity of GP against E. 
coli strain CFT073 in an agar diffusion assay (Paper IV). Briefly, bacteria from 
logarithmic culture at approximately 5 x104 CFU/ml was mixed with 1% low-
electrolyte agarose, vortexed and quickly poured intro Petri dish which was distributed 
evenly on the whole plate. After 30 min, several 3- mm holes were made in the agar 
layer and 3 µl of 10 mg/ml of GP was added into the holes. The agar was left for an 
hour at room temperature and then incubated overnight at 37°C. The antimicrobial 
potential of GP was determined by measuring the diameter of the zone of inhibition 
around the holes. 
 
3.12 EX VIVO INFECTION MODEL  
 
The GK rats which were administrated orally with either GP or water were sacrificed 
after 2 weeks and bladder tissues were collected (Paper IV). Immediately after 
collection, bladder tissue pieces were placed in DMEM medium (Gibco) with 1 µg/ml 
gentamicin with or without 108 CFU/ml E. coli CFT073 and incubated in a water bath 
at 37°C. This concentration of gentamicin was previously found to inhibit bacterial 
growth during the 2-hour incubation period without significantly affecting bacterial 
viability [89]. After 2 hours, pieces were transferred into RNAlater reagent (Qiagen) 
and kept at 4°C until processing for gene expression analyses. 
 
3.13 CELLS CULTURE, GP TREATMENT AND BACTERIAL INFECTION  
 
Bladder epithelial cells T24 and 5637 were cultured in McCoy’s  5A  modified  medium  
or RPMI 1640, respectively, containing 10% fetal bovine serum at 37°C and 5% CO2 
in a humidified incubator (Paper IV). For experiments, 105 cells/well were seeded in 
24-well tissue culture plates (Sarstedt Inc, Newton, NC, USA and Costar, Corning, 
NY, USA, respectively) and incubated for 24 hours. The cells were then treated with 
0.5, 0.1 and 0.05 mg/ml of GP. After another 24 hours, the cells were infected with 106 
CFU/ml E. coli CFT073 in medium with 0.5, 0.1 and 0.05 mg/ml of GP, respectively 
and gentamicin (final concentration of 40 µg/ ml). The infected cells were incubated at 
37º C in a humidified incubator with 5% CO2 for 24 hours. Thereafter, the medium 
was collected and centrifuged at 300 g for 10 min. The supernatant was collected and 
stored at -80˚C   for   further   analysis.   The   cells   on   the   plate  were   collected   for   RNA  
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extraction. Viability of the cells was not significantly affected by GP at the used 
concentrations as determined by XTT assay. 
 
3.14 ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA) 
 
The secreted IL-8 in cell culture supernatants was determined by ELISA using the 
Human CXCL8/IL-8 DuoSet (R&D   systems)   according   to   the   manufacturer’s  
recommendations (Paper IV). The ELISA microplate reader at 560 nm was used and 
concentrations in the samples were calculated with help of the standard curve. 
 
3.15 TOTAL RNA EXTRACTION AND CDNA SYNTHESIS (PAPER  IV) 
 
Total RNA isolation from bladder pieces was processed according to the 
manufacturers’   protocol   using  RNeasy  Mini  Kit   (Qiagen) (Paper IV). Tissue pieces 
were homogenized in RLT buffer containing β-mercaptoethanol using a mortar and 
pestle and subsequent passing through a QIAshredder; cells were collected by addition 
of the same lysis buffer. Tissue and cell lysates were then processed following the 
recommendations of the manufacturer. Total RNA at 1 µg of was transcribed into 
cDNA High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). The 
concentration and purity of RNA was determined with a Nanodrop. 
 
3.16 GENE EXPRESSION ANALYSIS 
 
Changes in gene expression were assessed by RT real-time PCR using TaqMan gene 
expression system (Applied Biosystems) (Paper IV). Primer/probe mixtures specific 
for human and rat IL6; human IL8 and rat CXCL1, the rat orthologue to IL8; and 
human cathelicidin antimicrobial peptides LL-37/hCAP18 (CAMP), RNase7, psoriasin 
(S100A7) and DEFB4 encoding human beta defensin 2 (HBD2) were used; human or 
rat GAPDH served as reference genes. Expression levels are presented as 2-ΔCT, and 
gene induction as 2-ΔΔCT compared to non-infected, non-treated samples. 
 
3.17 FLUORESCENCE IMMUNOCYTOCHEMISTRY 
 
Cells were grown on glass coverslips and treated as described above (Paper IV). Cells 
were fixed by incubation with 4% paraformaldehyde in PBS for 15 minutes at room 
temperature, permeabilized with 0.5% Triton X-100 in PBS for 10 minutes and then 
blocked with 5% BSA in permeabilization buffer for 30 minutes. Incubation with 
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primary antibodies diluted in buffer against psoriasin (1:800; Abcam), RNase7 (1:500; 
Icosagen), CAMP (1:50; Santa Cruz Biotechnologies) and HBD2 (1:50; Santa Cruz 
Biotechnologies) was performed at 4°C overnight, followed by incubation with an 
Alexa488-labeled secondary antibody (1:600; Invitrogen) for 1 hour at room 
temperature. Images were acquired on a Leica confocal microscope SP5 with a 40x or 
63x objective. In each experiment, 5 images were recorded per condition and images 
taken with 40x objective were used to quantify peptide expression with the microscope 
software (LAS AF Lite). 
 
3.18 STATISTICAL ANALYSIS 
 
All data were analyzed using Prism Graph Pad Software (CA, USA). The results were 
presented as mean ± SEM. For OGTT experiments, differences between experimental 
groups were analyzed using paired t-test (Paper I) and unpaired t-test (Paper III). The 
differences between means in the batch incubations and the mechanisms of insulin 
release were analyzed for significance using paired t-test (Paper II) and for Paper III, 
one-way ANOVA was performed, if significant followed by Bonferroni's Multiple 
Comparison Post Hoc Test. Data obtained from ex vivo analyses of rat tissue were 
overall analyzed by Mann Whitney test; data from cell culture experiments were 
analyzed by ANOVA with Dunnett’s   multiple   comparison   tests (Paper IV). 
Differences with P-values below 0.5 were considered statistically significant. 
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4 RESULTS AND DISCUSSIONS 
 
4.1 ANTIDIABETIC EFFECT OF ORAL BORAPETOL B COMPOUND, 
ISOLATED FROM THE PLANT TINOSPORA CRISPA, BY 
STIMULATING INSULIN RELEASE (PAPER I) 
 
In Paper I, we evaluated the antidiabetic properties of borapetol B (C1) isolated from 
Tinospora crispa in normoglycemic control Wistar (W) and spontaneously type 2 
diabetic Goto-Kakizaki (GK) rats. An acute oral administration of C1 reduced blood 
glucose levels in treated versus placebo groups in W (P<0.01) (Figure 4) and with 
decreased areas under the glucose curves (AUCs) (0 min to 120 min; P<0.001) and in 
GK (P<0.05) (Figure 5) with AUCs (0-120 min; P<0.01). Plasma insulin levels were 
increased by 2-fold in treated W and GK rats versus placebo group at 30 min (𝑃<0.05). 
The incubation of islets at different C1 concentrations at low and high glucose showed 
that C1 dose-dependently increased insulin secretion from W and GK isolated islets 
(Table 1). The perifusion of isolated islets indicated that C1 did not cause leakage of 
insulin by damaging islet beta cells both in W and GK rats since insulin release was 
stimulated only in the presence of C1. 
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Figure 4: Blood glucose level in the oral 
glucose tolerance test in W rats. 10 µg/100 
g of b.w of C1 (---) or Placebo (—) was 
given orally 30 minutes prior to the 
glucose challenge (0.2 g/100 g of b.w.). 
Data are presented as means ± SEM 
(n=5). **P<0.01 vs. Placebo; ***P<0.001 
vs. Placebo 
Figure 5: Blood glucose level in the oral 
glucose tolerance test in GK rats. 10 
µg/100 g of b.w of C1 (---) or Placebo (—
) was given orally 30 minutes prior to the 
glucose challenge (0.2 g/100 g of b.w.). 
Data are presented as means ± SEM 
(n=5). *P<0.05 vs. Placebo 
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Table 1: The effect of different concentrations of C1 at low (3.3 mM) and high (16.7 mM) glucose on 
insulin secretion from W (n=5) and GK (n=3) rat islets. 
 
Addition to incubation medium Insulin release (µU/islet/h) W islets GK islets 
Glucose (mM) C1 (µg/ml)   
3.3 None 2.4 ± 0.1 1.2 ± 0.2 
0.1 15.1 ± 2.2** 4.7 ± 0.3* 
1 19.5 ± 4* 7.5 ± 0.9* 
10 21.9 ± 2*** 10.5 ± 1.8* 
16.7 None 32.5 ± 1.8 13.6 ± 0.6 
0.1 48.8 ± 6# 20.6± 1.1# 
1 63.1 ± 8.9# 30.9 ± 3.8# 
10 164.5 ± 11.3### 57.3 ± 6.3# 
 
*P<0.05; **P<0.01; ***P<0.001 when compared with the control group 
 
Previous findings have shown the effectiveness of extract and isolated compounds from 
Tinospora crispa in the stimulation of insulin release and insulin sensitivity in normal 
and diabetic animal model [38,47-50]. We show that oral administration of C1 30 
minute before an oral glucose challenge significantly decreased blood glucose levels in 
W rats. This was most likely mediated through enhanced insulin secretion, since the 
plasma insulin level in treated W rats increased by 2-fold compared to the placebo 
group. This is further supported by our findings that C1 stimulates insulin secretion 
from isolated pancreatic islets, both in batch incubations and in perifusions. To further 
assess the insulinotropic properties of C1 in T2D, studies were performed in 
spontaneously diabetic GK rats.  
 
We now demonstrated that oral treatment with C1 decreased blood glucose levels in 
parallel with an increase in plasma insulin levels during the OGTT, not only in W rats 
but also in GK rats. In addition, C1 at different concentrations increased insulin release 
from GK rat islets in low and high glucose and the stimulatory effect was observed in a 
dose dependent manner. In the perifusions of islets experiment, C1 stimulated insulin 
secretion in both W and GK rat islets. The insulin secretion gradually returned to basal 
level on the removal of C1, supporting that C1 did not cause nonspecific insulin 
leakage by damaging islets beta cells.  
 
In conclusion, the results of this study show that C1 improves the diabetic condition in 
GK rats by stimulating insulin secretion. Further studies are needed to understand the 
mechanisms involved by which C1 induces insulin release from pancreatic islets. 
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4.2 THE POSSIBLE MECHANISMS BY WHICH BORAPETOL B (C1) 
STIMULATES INSULIN RELEASE FROM RAT ISLETS (PAPER II) 
 
In Paper II, we explored the mechanisms by which C1 stimulates insulin release in the 
isolated pancreatic islets of normoglycemic control W and GK rats via K-ATP 
dependent pathway. C1 significantly stimulated insulin release at both low and high 
glucose in W and GK rat islets. The opening of K-ATP channels by adding diazoxide 
inhibited insulin release at 16.7 mM glucose in W (P<0.01) and GK (P<0.05) rat islets 
compared to control (Table 2). Diazoxide decreased insulin response to C1 in W and in 
GK (both P<0.01) only at 16.7 mM glucose. The insulin release of both W and GK rat 
islets incubated with C1 + diazoxide + KCl was significantly higher (when compared 
with islets incubated either with C1 only or diazoxide + KCl) at both 3.3 mM and 16.7 
mM glucose.  
 
Table 2: Effect of diazoxide on the insulin response to C1 in the isolated W and GK rat islets. Results of 
insulin release (µU/islet) are the mean ± S.E.M of three batch incubations at each condition. 
 
 W rat islets GK rat islets 
Glucose (mM) 3.3 mM 16.7 mM 3.3 mM 16.7 mM 
Addition to the medium         
None 2.5 ± 0.3 30.9 ±1.4 1.2 ± 0.1 13 ± 0.2 
T.crispa C1 (10 µg/ml) 22.1 ± 0.4*** 140.8 ±5.1** 10 ± 0.3** 56.2 ± 2.7** 
Diazoxide (0.25 mM) 2.6 ± 0.1 3.6 ± 0.2** 1.2 ± 0.2 10.1 ± 0.5* 
Diazoxide (0.25 mM) + KCl (50 mM) 22.8 ± 2.3** 131.2 ± 7.7* 10.2  ± 1** 54 ± 5.5** 
T.crispa C1 (10 µg/ml) + Diazoxide (0.25 
mM) 23.6 ± 0.7## 85.4 ± 5.3## 9.9 ± 0.6 37.4 ± 3.4## 
T.crispa C1 (10 µg/ml) + KCl (50 mM) + 
Diazoxide (0.25 mM) 38.5 ± 1.2##† 155.7 ± 7.4#† 14.8 ± 0.3##† 84.5 ± 5.8#† 
 
*P<0.05;**P<0.01; ***P<0.001 when compared with control group with no addition 
 #P<0.05; ##P<0.01 when compared with group with only T.crispa C1 
†P<0.05 when compared with diazoxide + KCl 
 
Nifedipine decreased insulin release in W (P<0.05) and in GK (P<0.01) rat islets at 
16.7 glucose only (Table 3). In the presence of nifedipine, C1-induced insulin secretion 
of islets was decreased in W (P<0.01) and GK rat islets at 16.7 mM glucose. H89 and 
calphostin C inhibitors of PKA and PKC, respectively, did not affect the insulin 
response to C1 respectively in W and GK islets at both 3.3 mM and 16.7 mM glucose 
(Table 4). At 16.7 mM glucose, pertussis toxin decreased the insulin response to C1 in 
the W (P<0.01) and GK rat islets (P<0.05). When exploring the mechanisms of insulin 
release in the W and GK pancreatic islets, we showed that the C1 effect was exerted 
partly via K-ATP channels since diazoxide partly, but not totally suppressed C1 
stimulation at 16.7 mM glucose. C1 effect was also dependent on L-type Ca2+ channels 
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since nifedipine suppressed the insulin response to C1 at 16.7 mM. There was no 
modulation by PKA and PKC inhibitors. Furthermore, C1 effect was partly dependent 
on pertussis toxin sensitive Ge-protein.  
 
Table 3: Effect of nifedipine on the insulin response to C1 in the isolated W and GK rat islets. Results of 
insulin release (µU/islet) are the mean ± S.E.M of three batch incubations at each condition. 
 
 
*P<0.05;**P<0.01 when compared with control group with no addition 
#P<0.05; ##P<0.01when compared with group with only C1 
 
Table 4: Effect of H89 and calphostin C on the insulin response to C1 in the isolated Wistar and GK rat 
islets. Results of insulin release (µU/islet) are the mean ± S.E.M of three batch incubations at each 
condition. 
 
 W rat islets Gk rat islets 
Glucose 3.3 mM 16.7 mM 3.3 mM 16.7 mM 
Addition to the medium         
None 3.1 ± 0.2     31± 3.6 2.4 ± 0.7 15.3 ± 1.2 
H89 (10 µM) 4.4 ± 0.3 25.6 ± 1.2 2.1 ± 0.2 15.6 ± 0.9 
Calphostin C (1.5 µM) 5.0 ± 0.3 24.1 ± 1.5 1.8 ± 0.4 14.3 ± 1.1 
T.crispa C1 (10 µg/ml) 21.4 ± 3.2* 152.4 ± 8.3** 11.2 ± 1.2* 56 ± 2.4** 
T.crispa C1 (10 µg/ml) + H89 (10 µM) 20.1 ± 1.8* 159.7 ± 4.9** 8.0 ± 1.0** 45.7 ± 2.8* 
T.crispa C1 (10 µg/ml) + Calphostin C 
(1.5 µM) 21 ± 0.6** 150.5 ± 6.7** 6.6 ± 1.0* 53 ± 2.8* 
 
*P<0.05;**P<0.01 when compared with control group with no addition 
 
We showed that C1 significantly stimulated insulin release at both low and high 
glucose. The mechanism by which C1 stimulates insulin release in W and GK was 
partly mediated via K-ATP and L-type Ca2+ channels rat islets. The effect of C1 was 
also partly dependent on pertussis toxin sensitive Ge-protein at low and high glucose. 
C1 effect was not mediated via the PKA and PKC system. The effect of C1 is partly 
in contrast to the sulfonylureas drug which stimulates insulin by closing the K-ATP 
channel [90,91].  
 
 W rat islets GK rat islets 
Glucose 3.3 mM 16.7 mM 3.3 mM 16.7 mM 
Addition to the medium     
None 2.6 ± 0.2 30.3 ± 3.1 1.3 ± 0.2 13.4 ± 0.6 
T.crispa C1 (10 µg/ml) 24 ± 3.3* 157.5 ± 7.7** 10.5 ± 0.6** 59.3 ± 5.3* 
Nifedipine (10 µM) 2.3 ± 0.2 5.3 ± 0.7* 1 ± 0.1 4.4 ± 0.1** 
T.crispa C1 (10 µg/ml) + Nifedipine (10 
µM) 22.2 ± 1.6
** 132 ± 10**## 10.3 ± 0.5** 30.6 ± 3.2*# 
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4.3 EVALUATION OF ANTIDIABETIC EFFECTS OF GYNOSTEMMA 
PENTAPHYLLUM ON INSULIN RELEASE (PAPER III) 
 
In Paper III, the effects of GP water extract on GK rat blood glucose and serum 
insulin levels were determined. In addition, GP extract effects on mechanisms behind 
insulin secretion from GK rat islets were investigated. The oral glucose tolerance test 
was performed to identify the effects of GP on the blood glucose and insulin levels. 
After two-weeks’   treatment   with   GP extract, glucose tolerance was significantly 
improved. The mean blood glucose levels at 120 were decreased in the treated group as 
compared to the placebo group (11.0 ± 1.1 vs 13.9 ± 1.1 mM, respectively (Figure 6) 
with AUCs (0-120 min) for glucose being 639.6  ± 38.5 vs 842.4 ± 43.8) mM (P<0.01). 
Plasma insulin levels after GP treatment were significantly increased both at 0 min and 
after glucose stimulation at 30 and 120 min when compared with the control group 
(P<0.01) .  
 
Figure 6: Blood glucose level in the oral glucose tolerance test in GK rats after two-week treatment. GP 
(0.3 g/kg of body weight) (---) or placebo (—) was given orally daily for two weeks. Data are presented 
as means ± SEM (n=5). 
 
To identify if the oral administration of GP has an effect on insulin release, the 
pancreas of rat treated with GP for two-week were collected, and islets isolated for 
studies of insulin secretion. At 3.3 mM glucose, insulin release was not significantly 
different between islets of GK rats treated with GP as compared to islets from control 
GK rats (14.6 ± 1 vs 14.3 ± 1.9 µU/islet). However, insulin release at 16.7 mM glucose 
was significantly higher in islets from GP-treated rats as compared to islets from 
control rats (61.8 ± 4.9 vs 32.7  ± 2.8 µU/islet; P<0.001). 
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In separate in vitro experiments, isolated GK rat islets were incubated with different 
concentrations of GP to identify the insulin-stimulatory effect. At 3.3 mM glucose, GP 
at any concentration did not stimulate insulin release when compared to the control 
incubations (Figure 7). At 16.7 mM glucose, the addition of 5, 10 and 15 mg/ml GP 
dose-dependently stimulated insulin release 1.6-fold, 2.2-fold (P<0.01) and 3.6-fold 
(P<0.001), respectively, when compared to the control group.  
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Figure 7: Effect of different concentrations of GP (1,5,10,15 mg/ml) on the insulin secretion in GK rat 
islets (n=5). **P<0.01, ***P<0.001 (when compared with the control group at 16.7 mM glucose only). 
Results of insulin release (µU/islet/hour) are the means ± SEM of five independent experiments with 
three replicates for each experiment.  Differences between means were analyzed by one-way ANOVA, if 
significant followed by Bonferroni's Multiple Comparison Post Hoc Test. 
 
Our findings have shown that GP has a potent insulin-stimulating activity in the GK rat 
islets. Therefore, to further understand the mechanisms behind GP-stimulated insulin 
release, we have explored the different sequences of pancreatic beta cell stimulus-
secretion coupling for glucose [63]. We first elucidated the role of the ATP-sensitive 
potassium (K-ATP) channels. 
 
To understand if GP stimulates insulin release via the K-ATP channels, we used 
diazoxide. The opening of K-ATP channels by adding diazoxide (0.25 mM) inhibited 
insulin release by 63% at 16.7 mM glucose (Figure 8A). In addition, at 16.7 mM 
glucose, diazoxide decreased insulin response to GP from 78.1 ± 15.6 to 26 ± 17.0 
μU/islet  (P<0.001). The addition of potassium chloride (KCl) to islets incubated with 
diazoxide to depolarize the β-cells increased insulin release at both 3.3 mM and 16.7 
mM glucose compared to the control group. At 16.7 mM, the insulin response to GP + 
 22 
 
diazoxide and KCl was significantly higher compared to islets incubated with diazoxide 
+ KCl (at P<0.05). Diazoxide however did not affect the insulin response to GP at low 
glucose. 
 
To further understand if GP exerts its effect via L-type Ca2+ channel, nifedipine was 
used as an inhibitor of these channels [92]. At 16.7 mM glucose, GP stimulated insulin 
release by 2.6 fold (P<0.001) compared to the control (Figure 8B). The addition of 
nifedipine  (10  μM),  decreased  insulin  release  from  12.6  ±  1.7  to  6.5  ±  1.3  (μU/islet).  
Incubation with nifedipine and GP at 16.7 mM glucose decreased insulin secretion 
significantly compared to secretion induced by GP only, from 32.8 ± 4.5 to 19.4 ± 1.3 
μU/islet  (P<0.01). 
 
PKA or PKC pathways potentiate the insulin response to a metabolic stimulus [93]. To 
understand if GP exerts its effect via the PKA and PKC pathways, H89 (PKA inhibitor) 
and calphostin C (PKC inhibitor) were used. Incubation of islets at 16.7 mM glucose 
with GP stimulated insulin release 2.2-fold (P<0.01) (Figure 8C).  H89   (10  μM)  and  
calphostin  C  (10  μM)  decreased  insulin  release  from  22.1  ±  2.8  to  7.7  ±  3.9  and  to  5.4  ±  
0.2   μU/islet,   respectively   at   16.7   mM   glucose compared to the control group. H89 
decreased the insulin response to GP from  48.8  ±  0.9  to  26.07  ±  3.2  μU/islet  (P<0.05). 
Calphostin C did not affect the insulin response to GP at 16.7 mM glucose. 
 
To understand if GP stimulates insulin release via exocytotic Ge proteins, pertussis 
toxin (PTX) was used as an inhibitor. PTX prevents the G proteins from interacting 
with their associated G protein-coupled receptors [21]. The pre-incubation of GK rat 
islets with pertussis toxin in the presence of GP at 11.1 mM glucose decreased the 
insulin secretion compared to the control group, from 29.6 ± 2.2 to 13.8 ± 0.7 µU/islet 
at 16.7 mM glucose (P<0.05) (Figure 8D). 
 
Our present findings suggest that GP-induced insulin release is partly mediated via K-
ATP and L-type Ca2+ channels. GP-induced insulin secretion is also modified by the 
PKA, but not the PKC, pathway. It seems plausible that GP, at least partly, exerts its 
stimulatory effects on insulin exocytosis, since preincubation of islets with the G-
protein inhibitor pertussis toxin also decreased GP-induced insulin release. 
 
In conclusion, our findings have shown that GP acts via K-ATP and L-type Ca2+ 
channels. In addition, GP seems to interact with the PKA system and partially via 
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exocytotic Ge-proteins. Thus, it seems possible that these effects, at least to some 
extent, are exerted by phanoside, a gypenoside that has been purified from GP [63,64]. 
Phanoside was also shown to exert its insulin-stimulatory effect distal to K-ATP 
channels and L-type Ca2+ channels, i.e. mainly on the exocytotic machinery of the beta 
cells [63,65]. 
 
 
Figure 8: The mechanisms of insulin release of GP in the isolated GK rat islets via 
 (A) K-ATP channel, opened by diazoxide (D) and depolarized by kalium chloride (KCl) at 3.3 mM and 
16.7 mM glucose (n=5). ***P<0.001 (when compared with control group with no addition); #P<0.05 
(when compared with group with only D+KCl); ¤P<0.05, ¤¤¤P<0.001 (when compared with group with 
only GP); αααP<0.001 (when compared with D) ab 
(B) Ca2+ channel, inhibited by nifedipine (N) at 16.7 mM glucose (n=6). ***P<0.001 (when compared 
with control group with no addition); ##P<0.01 (when compared with group with only GP); αP<0.05 
(when compared with N)ab 
(C) PKA and PKC mediators, inhibited by H89 and calphostin C (n=3) at 3.3 mM and 16.7 mM glucose. 
**P<0.01 (when compared with control group with no addition); #P<0.01 (when compared with group 
with only GP) ab 
(D) G protein, inhibited by pertussis toxin (n=3). *P<0.05, **P<0.01 (when compared with control group 
with no addition at 16.7 mM glucose); #P<0.05 (when compared with islets incubated with GP at 16.7 
mM glucose without exposure to pertussis toxin) using paired t-testa 
aResults of insulin release (µU/islet) are the mean ± S.E.M. b Differences between means were analyzed 
by one-way ANOVA, if significant followed by Bonferroni's Multiple Comparison Post Hoc Test. 
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4.4 GYNOSTEMMA PENTAPHYLLUM EXHIBITS ANTI-INFLAMMATORY 
PROPERTIES AND MODULATES ANTIMICROBIAL PEPTIDE 
EXPRESSION IN THE URINARY BLADDER (PAPER IV) 
 
In Paper IV, we investigated if oral administration of GP impacts the inflammatory 
response to E. coli in the urinary bladder of diabetic GK rats and further the influence 
in vitro in epithelial bladder cell lines. We also investigated if GP treatment modulates 
the expression of antimicrobial peptides in response to E. coli. 
 
At baseline, no significant difference in the expression of pro-inflammatory IL-6 and 
CXCL-1, the rat homolog for human IL-8, could be established (Figure 9A). In 
response to bacteria, our results showed that GP reduced the IL-6 levels in the rat 
bladder tissue compared to the control group on mRNA level (P<0.05). The CXCL1 
induction was also attenuated (Figure 9B). 
 
 
Figure 9: The pro-inflammatory response to E. coli is reduced in bladder tissue from GP-treated 
rats. Bladders were removed from GK rats (Co) or GK rats receiving GP for two weeks (GP). Total 
RNA was extracted directly (A) or after a 2-hour ex vivo infection with uropathogenic E. coli in the 
presence of sublethal concentrations of gentamicin (1 µg/ml) (B). Relative expression levels are 
expressed as 2-ΔCT in relation to GAPDH levels (A) and as 2-ΔΔCT in relation to non-infected control tissue 
incubated alongside (B). Differences between control and GP-treated rats were analyzed by two-tailed t-
test, *P<0.05; gene induction by E. coli was evaluated by one-tailed, paired t-test between non-infected 
and infected tissue pieces from the same animal, #P<0.05, ###P<0.001. 
 
 
We then confirmed these initial findings with in vitro experiments using the epithelial 
bladder cell lines, T24 and 5637. Our results in T24 cells showed that IL-6 induction 
was reduced after GP treatment at 0.1 and 0.5 mg/ml in response to bacteria, however 
no significant difference was observed when compared to untreated cells (Figure 10A). 
A similar pattern was seen in the IL-8 induction which was reduced in the cells treated 
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with GP at 0.5 mg/ml (P<0.05) and 0.1 mg/ml on mRNA level when compared to the 
untreated cells infected with E.coli (Figure 10B). On protein level, the IL-8 was 
significantly downregulated at 0.5 mg/ml (Figure 10C). Using 5637 cell line, no 
induction of IL-6 was observed in response to E.coli (Figure 10D). GP significantly 
attenuated the IL-8 level at 0.05 (P<0.05), 0.1 (P<0.05) and 0.5 mg/ml (P<0.001) on 
mRNA level when compared with the cells infected with only E.coli (Figure 10E).  
 
 
Figure 10: GP reduces bacteria-mediated induction of IL-6 and IL-8 in bladder epithelial cells.  
Bladder epithelial cells T24 (A-C) and 5637 (D+E) were treated with GP at indicated concentration for 
24 hours and infected with E. coli in the presence of 40 µg/ml gentamicin for another 24 hours. Gene 
expression (A+B, D+E) was determined by RT real-time PCR and the influence of GP on bacteria-
mediated gene induction is expressed in relation to non-infected, non-treated control cells (Co). Secretion 
of IL-8 into the cell culture medium was quantified by ELISA (C). Differences to control cells are 
indicated by #P<0.05, ##P<0.01 and ###P<0.001; differences to infected, non-treated cells are indicated by 
*P<0.05 and ***P<0.001;;   analysis   was   performed  with   ANOVA   and  Dunnett’s  multiple   comparison  
test. Results from 5-6 (A-C) or 3 (D+E) experiments are shown with mean and SEM. 
 
 
Our results have confirmed that GP exerts anti-inflammatory effects by suppressing the 
pro-inflammatory response to E.coli both ex vivo and in vitro which could protect the 
tissue from destruction. However, the reduction of anti-inflammatory levels by GP 
might decrease the immune response against invading pathogens to a critical limit. 
Therefore, we sought to investigate whether GP activates alternative pathways in the 
host defense against bacteria. Our results demonstrated that GP modulates expression 
of antimicrobial peptides. 
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In the bladder epithelial cell line 5637, psoriasin (S100A7) expression was significantly 
induced at 0.05, 0.1 and 0.5 mg/ml (P<0.001) (Figure 11A) whereas the expression 
level of human beta defensin 2 (DEFB4) was downregulated by GP (Figure 11B).  
Furthermore, cathelicidin antimicrobial peptide LL-37/hCAP18 (CAMP) levels was 
also increased (Figure 12A). The expression of RNase 7 level was not significantly 
affected (Figure 12B). Microscopic analyses of cells treated with GP corroborated the 
result on transcript level (Figures 11C and 12C). In further experiments, the 
antimicrobial peptide levels found in the animals treated with GP supported the results 
obtained from cell culture. Transcription of S100A7A was also higher in bladder tissue 
after ex vivo infection in GP-treated GK rats, as compared to control rats, and a similar 
trend was seen for CAMP (data not shown). This study has confirmed that GP has anti-
inflammatory effects by suppressing the IL-6 and IL-8 inductions and compensates 
with an increased AMP expression. 
 
  
 
Figure 11: GP modulates the 
expression of antimicrobial peptides 
in bladder epithelial cells. Bladder 
epithelial cells 5637 were treated with 
GP at indicated concentrations for 24 
hours. The expression of antimicrobial 
peptides psoriasin (S100A7) (A+C) 
and human beta defensin 2 (DEFB4) 
(B) was evaluated by RT real-time 
PCR (A+B) and psoriasin by 
immunofluorescence microscopy (C). 
Analysis was performed with 
ANOVA   and   Dunnett’s   multiple  
comparison test. Results from 4 
(A+B) or 2 (B) independent 
experiments are shown as mean and 
SD. 
Figure 12: GP modulates the 
expression of antimicrobial 
peptides in bladder epithelial cells. 
Bladder epithelial cells 5637 were 
treated with GP at indicated 
concentrations for 24 hours. The 
expression of CAMP (A+C) and 
RNase 7 (B) was evaluated by RT 
real-time PCR (A+B) and CAMP by 
immunofluorescence microscopy (C). 
Analysis was performed with 
ANOVA   and   Dunnett’s   multiple  
comparison test. Results from 4 
(A+B) or 2 (B) independent 
experiments are shown as mean and 
SD. 
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Both NF-κB   and   mitogen-activated protein kinases (MAP kinases) are activated by 
tumor  necrosis   factor   α   (TNFα)   [30]. GP has been shown previously to exhibit anti-
inflammatory action by inhibition of nuclear  factor  (NF)  κB  signaling [68]. Gypenoside 
isolated from GP has been shown to inhibit NF-κB activation via a PPAR-α-dependent 
pathway in murine macrophages [94]. In contrast, some gypenosides have been 
demonstrated to promote phosphorylation of the MAP kinase ERK1/2 [95]. In another 
study, GP compounds have been reported to suppress expression of IL-1β,   IL-6 and 
COX-2 mRNA in LPS-induced RAW 264.7 macrophage cells which may be used to 
promote the potential application of GP in functional foods [56].  
 
Our results suggested that GP exerts its anti-inflammatory effects by suppressing IL-8 
and IL-6 via the NF-κB   signaling pathway and that it activates psoriasin and CAMP 
peptides via the MAP kinase. Apart from NF-κB,  mMAP  kinases have also been shown 
to be involved in the regulation of AMP expression [96,97].  
 
In conclusion, our study has confirmed that an oral consumption of GP leads to a 
reduction of the pro-inflammatory response in the bladder epithelium of type 2 diabetic 
rat in response to E. coli infection. The upregulation of neutrophil-attractant AMP 
psoriasin might compensate the suppression of IL-8 level but at the same time also 
inhibit E. coli directly. Thus, the administration of GP might be useful to support innate 
defence mechanisms from long term complications in T2D patients.   
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5 THESIS SUMMARY 
 
We have investigated the antidiabetic effects of two traditional plants, borapetol B (C1) 
isolated from Tinospora crispa and Gynostemma pentaphyllum (GP) using an animal of 
type 2 diabetes, the Goto Kakizaki rat. The anti-inflammatory and anti-microbial 
effects of GP were also analyzed. Therefore, the following conclusions can be made 
from our results; 
 
Paper I – The study confirms that an oral administration of C1 improves the diabetic 
condition in GK rats which was most likely mediated through enhanced insulin 
secretion. This is further supported by the in vitro study showing stimulated insulin 
secretion when C1 was added in batch incubation and perifusion experiments. 
 
Paper II – This study provides evidence that the C1 has an effect partly via K-ATP and 
L-type Ca2+channels and the major stimulatory effect might be on the exocytosis of 
insulin. The findings may be important for drug development in the future. 
 
Paper III – This study indicates that the anti-diabetic effects of GP are associated with 
increased level of insulin release from the islets. The mechanisms of insulin release of 
GP involved might be partly mediated via K-ATP, L-type Ca2+ channels, PKA system 
and partly dependent on pertussis toxin sensitive Ge-protein at high glucose. These 
findings may be used to promote the potential use of GP as an anti-diabetic drug. 
 
Paper IV – This study demonstrates that the oral administration of GP exhibits both 
anti-inflammatory properties and modulates antimicrobial peptide expression in the 
urinary bladder. Further GP may be a promising candidate to support the innate 
immune system and to protect from long-term complications in diabetic patients.  
 
In conclusion, both C1 and GP provide a potential source of anti-diabetic drugs which 
exert effects via stimulating insulin secretion. Furthermore, GP has the potential to 
support innate immunity defence mechanisms in diabetes. 
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